| Dear Subscriber, I'm standing outside the Capitol building right now, where history is about to be made. Inside, I believe Congress is reviewing H.R. 2407 -– possibly the most significant medical legislation since Medicare's creation. This bill has one primary goal: to give America's 65 million seniors access to a revolutionary blood test that can detect cancer at Stage One… when survival rates can soar up to 1,400%. For seniors and their families, this bill is nothing short of a miracle. But for investors who understand what's really happening, it represents something else entirely... A once-in-a-generation opportunity to profit from what could be the biggest medical breakthrough of our lifetime. You see, while most investors are focused on the bill itself... I've identified the one company I believe is best positioned to receive what could amount to a government-granted monopoly on cancer screening for every senior in America. It has already locked down this market with... - Multiple patents on their "stage one" cancer detection technology
- Possibly the largest cancer DNA database in the world
- And even an impressive network of partnerships that spans the entire healthcare industry.
And right now, even before this bill has passed, they're working directly with Medicare on a groundbreaking 50,000-person trial. If Medicare approves coverage -– which I believe is imminent -– this tiny $1.1 billion company could secure a 50X growth runway practically overnight. That translates to potential gains of 5,000% or more in the coming years for investors who act now. But you must move quickly. If this bill advances through Congress, Wall Street will catch on and the opportunity will vanish. Click here now to get the full details before this stock takes off. Good investing, Alex | 
Tidak ada komentar:
Posting Komentar